Stoke Therapeutics (STOK) Equity Ratio (2022 - 2025)
Historic Equity Ratio for Stoke Therapeutics (STOK) over the last 4 years, with Q3 2025 value amounting to 0.86.
- Stoke Therapeutics' Equity Ratio rose 807.33% to 0.86 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.86, marking a year-over-year increase of 807.33%. This contributed to the annual value of 0.84 for FY2024, which is 2068.84% up from last year.
- Latest data reveals that Stoke Therapeutics reported Equity Ratio of 0.86 as of Q3 2025, which was up 807.33% from 0.87 recorded in Q2 2025.
- In the past 5 years, Stoke Therapeutics' Equity Ratio ranged from a high of 0.87 in Q2 2025 and a low of 0.68 during Q1 2024
- Over the past 4 years, Stoke Therapeutics' median Equity Ratio value was 0.76 (recorded in 2023), while the average stood at 0.77.
- As far as peak fluctuations go, Stoke Therapeutics' Equity Ratio tumbled by 985.72% in 2024, and later surged by 2578.72% in 2025.
- Stoke Therapeutics' Equity Ratio (Quarter) stood at 0.72 in 2022, then dropped by 3.2% to 0.7 in 2023, then rose by 20.69% to 0.84 in 2024, then increased by 1.41% to 0.86 in 2025.
- Its Equity Ratio stands at 0.86 for Q3 2025, versus 0.87 for Q2 2025 and 0.86 for Q1 2025.